Guest Editor’s Memo

We are thrilled to bring this issue of Advances in Pulmonary Hypertension to you, which highlights some of the fruits of basic and clinical research in pulmonary hypertension. We have invited accomplished PH experts to help us navigate through some of the increasingly complex challenges in the diagnosis and treatment of PH. First, we have included all the scientific abstracts presented at the PHA 2022 International Pulmonary Hypertension Conference.Next, Drs. Jennifer Keen, Nadine Al-Naamani, and Corey Ventetuolo provide a focused review on emerging therapies for the management of pulmonary arterial hypertension (PAH). They summarize selected and most promising novel pharmaceuticals currently on the horizon and in clinical trials that are targeting new pathways in PAH.In August of 2022, the European Society of Cardiology and the European Respiratory Society published guidelines for the diagnosis and management of pulmonary hypertension (PH). This recent guideline now lowers the pulmonary vascular resistance from > 3 Wood units down to >2 Wood Units to meet the criteria for pre-capillary PH. Drs. Bradley Maron and Georgios Triantafyllou take us back to 1973, when the diagnosis of PH only required a mean PAP of >25 mmHg, and then review the subsequent literature that forms the basis for the revised definition. Dr. Robert Frantz provides a counterpoint to the lowering of the upper limit of PVR by highlighting the problems with the revised definition of pre-capillary PH, and how it might be practically implemented in clinical practice. Finally, Drs. Vallerie McLaughlin, Marc Humbert, Charles Burger, and Hilary DuBrock discuss the pros and cons of these new guidelines in-depth in a roundtable format.We immensely thank all of our contributing authors for sharing their experience and insights. We sincerely hope you enjoy reading this issue of Advances in Pulmonary Hypertension.